SCHEMBL899715

SCHEMBL899715

Clc1ncnc2scc(I)c12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
HTT P42858 4/20 0.53
KMT2A Q03164 1/20 0.53
LMNA P02545 3/20 0.50
ALDH1A1 P00352 2/20 0.50
NPSR1 Q6W5P4 2/20 0.46
PIP4K2C Q8TBX8 2/20 0.43
CHEK1 O14757 1/20 0.43
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40
GPR55 Q9Y2T6 1/20 0.40
MAP4K4 O95819 4/20 0.39
CLK2 P49760 4/20 0.39
MAP4K2 Q12851 4/20 0.39
DYRK1A Q13627 4/20 0.39
CLK4 Q9HAZ1 4/20 0.39
CSNK2A1 P68400 4/20 0.39
DYRK3 O43781 3/20 0.39
EGFR P00533 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2185553 0.79 MAPT (0.56) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL868188 0.78 MAPT (0.60) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL2185527 0.76 SMN1; SMN2 (0.58) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL14293290 0.76 MAPT (0.53) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL15743366 0.76 KDR (0.53) HTTPIP4K2CCHEK1MAP4K4CLK2
SCHEMBL30323242 0.76 MAPT (0.53) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL438061 0.76 MAPT (0.53) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL3796436 0.72 SMN1; SMN2 (0.50) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL3795260 0.72 MAPT (0.49) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL2185177 0.69 MAPT (0.46) MAPTSMN1; SMN2HTTKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313572-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2025-10-09 US disclosed
WO-2025106634-A1 MCL-1 INHIBITOR COMPOUNDS AND USE IN ANTIBODY DRUG CONJUGATES GENENTECH, INC. (US) 2025-05-22 WO disclosed
US-20250092062-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2025-03-20 US disclosed
US-20250059208-A1 KRAS MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2025-02-20 US disclosed
US-20250051337-A1 INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-02-13 US disclosed
US-20240228509-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2024-07-11 US disclosed
US-20230399340-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2023-12-14 US disclosed
US-20230183261-A1 Macrocyclic MCL-1 Inhibitors and Methods of Use ABBVIE INC (US) 2023-06-15 US disclosed
US-20220259226-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2022-08-18 US disclosed
EP-3988555-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE AbbVie Inc. (US) 2022-04-27 EP disclosed
CN-104725397-A Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them SERVIER LAB 2015-06-24 CN disclosed
EP-2886545-A1 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2015-06-24 EP disclosed
EP-2886545-A1 New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2015-06-24 EP disclosed
WO-2012044993-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING OR PREVENTING NEURODEGENERATIVE DISEASES OR DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2012-04-05 WO disclosed
WO-2012044993-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING OR PREVENTING NEURODEGENERATIVE DISEASES OR DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2012-04-05 WO disclosed
US-8008487-B2 Substituted thieno[2,3-D]pyrimidines as fungicides DOW AGROSCIENCES LLC (US) 2011-08-30 US disclosed
EP-1802632-B1 THIENO-PYRIMIDINE COMPOUNDS HAVING FUNGICIDAL ACTIVITY DOW AGROSCIENCES LLC (US) 2011-07-13 EP disclosed
EP-1802632-A1 THIENO-PYRIMIDINE COMPOUNDS HAVING FUNGICIDAL ACTIVITY Dow AgroSciences LLC (US) 2007-07-04 EP disclosed
WO-2006047397-A1 THIENO-PYRIMIDINE COMPOUNDS HAVING FUNGICIDAL ACTIVITY DOW AGROSCIENCES LLC (US) 2006-05-04 WO disclosed
US-20060089370-A1 Thieno-pyrimidine compounds having fungicidal activity BREWSTER WILLIAM K 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089370-A1 Thieno-pyrimidine compounds having fungicidal activity TYMP, DPM1, TYMS MAPT 2484/4885SMN1; SMN2 1805/4885HTT 3139/4885
US-20240228509-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 MAPT 4497/4885SMN1; SMN2 605/4885HTT 1383/4885
US-20250051337-A1 INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF STK3, STK4, STK36 MAPT 915/4885SMN1; SMN2 2800/4885HTT 2998/4885
US-20230183261-A1 Macrocyclic MCL-1 Inhibitors and Methods of Use MCL1, BCL2A1, BCL2L10 MAPT 4497/4885SMN1; SMN2 605/4885HTT 1383/4885
US-20250092062-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 MAPT 4497/4885SMN1; SMN2 605/4885HTT 1383/4885
US-20250313572-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 MAPT 4497/4885SMN1; SMN2 605/4885HTT 1383/4885
US-20220259226-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 MAPT 4499/4885SMN1; SMN2 609/4885HTT 1381/4885
US-20230399340-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 MAPT 4497/4885SMN1; SMN2 605/4885HTT 1383/4885
US-20250059208-A1 KRAS MODULATING COMPOUNDS KRAS, NRAS, HRAS MAPT 3563/4885SMN1; SMN2 3325/4885HTT 1596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.